Tyvaso

Description

Tyvaso (treprostinil)

Background
Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause right-sided heart failure and death (1, 2). Tyvaso is indicated for treatment of pulmonary arterial hypertension (PAH) which is classified by WHO as Group 1. Tyvaso is used to treat pulmonary arterial hypertension (PAH, high blood pressure in the lungs) to improve exercise ability (1).

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

WHO Group 1: Pulmonary Arterial Hypertension (PAH)
1.1 Idiopathic (IPAH)
1.2 Heritable PAH
   1.2.1 Germline mutations in the bone morphogenetic protein receptor type 2 (BMPR2)
   1.2.2 Activin receptor-like kinase type 1 (ALK1), endoglin (with or without hereditary hemorrhagic telangiectasia), Smad 9, caveolin-1 (CAV1), potassium channel super family K member-3 (KCNK3)
   1.2.3 Unknown
1.3 Drug-and toxin-induced
1.4 Associated with:
   1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
1’. Pulmonary vena-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
1”. Persistent pulmonary hypertension of the newborn (PPHN)

**WHO Group 2: Pulmonary Hypertension Owing to Left Heart Disease**

2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies

**WHO Group 3: Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia**

3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities

**WHO Group 4: Chronic Thromboembolic Pulmonary Hypertension <CTEPH!**

**WHO Group 5: Pulmonary Hypertension with Unclear Multifactorial Mechanisms**

5.1 Hematologic disorders: Chronic hemolytic anemia, myeloproliferative disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher’s disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis, segmental PH

The American College of Chest Physicians (ACCP) has published an updated clinical practice guidelines for treating PAH (2). These guidelines use the New York Heart Association (NYHA) functional classification of physical activity scale to classify PAH patients in classes I-IV based
on the severity of their symptoms (3). Tyvaso is indicated for patients with NYHA Functional Class III symptoms (1).

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>Class II</td>
<td>Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>Class III</td>
<td>Patients with pulmonary hypertension resulting in marked limitation of physical activity. These patients are comfortable at rest, but less than ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</td>
</tr>
<tr>
<td>Class IV</td>
<td>Patients with pulmonary hypertension resulting in inability to perform any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present at rest, and discomfort is increased by any physical activity.</td>
</tr>
</tbody>
</table>

**Regulatory Status**

Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%) (1).

The safety and efficacy of Tyvaso have not been established in patients with significant underlying lung disease (such as asthma or chronic obstructive pulmonary disease). Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect. Tyvaso is a pulmonary and systemic vasodilator, concomitant administration of Tyvaso with diuretics, antihypertensive agents or other vasodilators may increase the risk of symptomatic hypotension. In patients with low systemic arterial pressure, Tyvaso may cause symptomatic hypotension (1).

Tyvaso inhibits platelet aggregation so there may be an increased risk of bleeding, particularly in patients receiving anticoagulants (1).

Safety and efficacy in pediatric patients have not been established. Clinical studies of Tyvaso did not include patients younger than 18 years to determine whether they respond differently from older patients (1).

**Related policies**
Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Tyvaso may be considered medically necessary for treatment of patients 18 years of age or older with pulmonary arterial hypertension (PAH), WHO Group I and if the conditions indicated below are met.

Tyvaso may be considered investigational in patients under the age of 18 and for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have ALL of the following:

1. Pulmonary Arterial Hypertension (PAH) - WHO Group I

2. NYHA functional classification of physical activity - Class III

Prior – Approval Renewal Requirements

Age 18 years of age or older

Diagnoses

Patient must have ALL of the following:

1. Pulmonary Arterial Hypertension (PAH) - WHO Group I

2. Symptoms have improved or stabilized

Policy Guidelines
Pre – PA Allowance
None

Prior - Approval Limits
Duration 2 years

Prior – Approval Renewal Limits
Same as above

Rationale

Summary
Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence of left ventricular failure. This condition can progress to cause right-sided heart failure and death (1). Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with NYHA class III symptoms (1).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Tyvaso while maintaining optimal therapeutic outcomes.

References

Policy History
<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2012</td>
<td>Updated the NYHA indication to only Class III symptoms.</td>
<td></td>
</tr>
<tr>
<td>March 2013</td>
<td>Annual editorial review and reference update</td>
<td></td>
</tr>
<tr>
<td>March 2014</td>
<td>Annual review</td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Updates</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>March 2015</td>
<td>Annual editorial review and reference update.  Addition of age 18</td>
<td></td>
</tr>
<tr>
<td>June 2016</td>
<td>Annual editorial review and reference update.  Updated PAH classifications</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Policy number change from 5.06.08 to 5.40.13</td>
<td></td>
</tr>
<tr>
<td>September 2017</td>
<td>Annual editorial review and reference update</td>
<td></td>
</tr>
<tr>
<td>September 2018</td>
<td>Annual review and reference update</td>
<td></td>
</tr>
<tr>
<td>September 2019</td>
<td>Annual editorial review. Changed approval duration from lifetime to 2 years</td>
<td></td>
</tr>
</tbody>
</table>

**Keywords**

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on September 13, 2019 and is effective on October 1, 2019.